Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II study of Pritumumab for the treatment of Brain Cancer

Next Previous
X
Search
Trial Profile

A Phase II study of Pritumumab for the treatment of Brain Cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pritumumab (Primary)
  • Indications Brain cancer; Glioma
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Jan 2024 According to Nascent Biotech media release, the FDA has cleared clinical trial application to begin this Phase II study for the treatment of Brain Cancer.
    • 18 Apr 2023 According to Nascent Biotech media release, the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the next phase in the development of Pritumumab; Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB has also been submitted to the FDA. company anticipates initial comments from the FDA approximately 30 days from the date of filing.
    • 16 Sep 2022 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top